What Ventyx Biosciences, Inc.'s executives and directors are doing with their own shares, from SEC Form 3/4/5 filings — separating what the filings state (awards, withholding, disclosed plans) from what only the pattern of dates shows.
| 3 months | 12 months | |
|---|---|---|
| Open-market buys | 0 | 0 |
| Sells | 0 | 2 |
| Total trades | 0 | 13 |
| 3 months | 12 months | |
|---|---|---|
| Acquired | 0 | 156,365 |
| Disposed | 0 | 7,095,890 |
| Net activity | +0 | −6,939,525 |
View rich charts and dive into the patterns of specific insiders — who is accumulating, who is winding down, and which sale explanations the filings actually support.
| Insider | Relation | Date | Transaction | Shares | Price | Value | Shares held |
|---|---|---|---|---|---|---|---|
| Subramaniam Somu | Director | Mar 04 | Disposition to Issuer · D | −3,337,495 | — | — | 0 |
| Mohan Raju | CEO AND PRESIDENT | Mar 04 | Disposition to Issuer · D | −2,372,863 | — | — | 0 |
| Forman Mark S | Chief Medical Officer | Mar 04 | Disposition to Issuer · D | −6,000 | — | — | 0 |
| Gonzales Roy | Senior VP, Finance | Mar 04 | Disposition to Issuer · D | −5,313 | — | — | 0 |
| Nuss John | CHIEF SCIENTIFIC OFFICER | Mar 04 | Disposition to Issuer · D | −489,481 | — | — | 0 |
| Gujrathi Sheila | Director | Mar 04 | Disposition to Issuer · D | −130,000 | — | — | 0 |
| Subramaniam Somu | Director | Feb 27 | Other Transaction · J | −694,718 | — | — | 3,337,495 |
| Mohan Raju | CEO AND PRESIDENT | Dec 18 | Open-market sale · S | −47,345 | $7.72 | −$365K | 2,372,863 |
| Nuss John | CHIEF SCIENTIFIC OFFICER | Dec 18 | Open-market sale · S | −12,675 | $7.72 | −$97.8K | 489,481 |
| Mohan Raju | CEO AND PRESIDENT | Dec 17 | Exercise / conversion · M | +116,668 | — | — | 2,420,208 |
| Nuss John | CHIEF SCIENTIFIC OFFICER | Dec 17 | Exercise / conversion · M | +34,930 | — | — | 502,156 |
| Forman Mark S | Chief Medical Officer | Nov 17 | Grant / award · A | +3,000 | $1.03 | +$3.09K | 6,000 |
| Gonzales Roy | Senior VP, Finance | Nov 17 | Grant / award · A | +1,767 | $1.03 | +$1.82K | 5,313 |
| Forman Mark S | Chief Medical Officer | May 15 | Grant / award · A | +3,000 | $1.03 | +$3.09K | 3,000 |
| Gonzales Roy | Senior VP, Finance | May 15 | Grant / award · A | +1,750 | $1.03 | +$1.8K | 3,546 |
| Nuss John | CHIEF SCIENTIFIC OFFICER | Apr 02 | Open-market sale · S | −1,887 | $1.07 | −$2.02K | 467,226 |
| Subramaniam Somu | Director | Mar 28 | Other Transaction · J | −1,335,450 | — | — | 4,032,213 |
| Mohan Raju | CEO AND PRESIDENT | Mar 28 | Exercise / conversion · M | +11,844 | — | — | 2,303,540 |
| Nuss John | CHIEF SCIENTIFIC OFFICER | Mar 28 | Exercise / conversion · M | +4,531 | — | — | 469,113 |
| Subramaniam Somu | Director | Mar 10 | Other Transaction · J | −1,735,306 | — | — | 5,367,663 |
Loading...
